Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

New Compound Could Wake Up Immune Cells to Fight Cancer

Discovery of MK-1088 as a Potent A2A/A2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy.

PubMed1 min readAI-assisted summary
Editorial illustration for Discovery of MK-1088 as a Potent A2A/A2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy.
Editorial illustration

Summary

Tumors have a clever way of hiding from our natural defenses. They create a surrounding environment packed with a chemical called adenosine. When this chemical connects to specific docking stations on immune cells, called A2A and A2B receptors, it essentially puts the immune cells to sleep. Because of this, the cells stop performing their usual protective duties, like releasing inflammatory signals or presenting targets for the immune system to attack.

To solve this problem, scientists have designed a new series of compounds that block both the A2A and A2B receptors simultaneously. By plugging these docking stations, the new compounds stop adenosine from shutting down the immune response. Following a successful discovery process, researchers identified a standout compound named MK-1088. This newly optimized drug has the potential to reverse the tumor's suppressive effects and restore the body's natural ability to hunt down cancer cells.

While these findings are exciting, the research is currently in its early stages. The published study focuses entirely on preclinical drug discovery in the laboratory, meaning the treatment has not yet been tested in patients. However, based on its strong performance so far, MK-1088 has officially been selected to progress into initial human clinical trials.

Why it matters.

If MK-1088 proves safe and effective in humans, it could represent a major step forward for cancer immunotherapy. The drug is being developed for potential use as a standalone treatment or in combination with widely used immunotherapies known as anti-PD-1 and anti-PD-L1 antibodies. Since these existing treatments also aim to unleash the immune system, combining them with MK-1088 could help overcome the resistance many patients experience when tumors actively suppress immune cell activity.

Unlocking the hostile environment surrounding a tumor remains one of the biggest challenges in modern cancer research. By disabling the adenosine trap that puts immune cells to sleep, this new class of dual-blocking drugs might eventually provide a critical lifeline for patients whose cancers do not respond to standard treatments.

From the source

The story in numbers.

Compound number identified as clinical candidate MK-1088
46
Adenosine receptor subtypes targeted for dual blockade (A2AR and A2BR)
2
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
New Compound Could Wake Up Immune Cells to Fight Cancer — Daily Strand